Important trial hit for Opdivo/Yervoy in lung cancer

22 October 2019
opdivo__bristol-myers_large-1-

New Jersey, USA-based cancer specialist Bristol-Myers Squibb (NYSE: BMY) has announced positive data in lung cancer for its immuno-oncology combination, Opdivo (nivolumab) plus low-dose Yervoy (ipilimumab).

The firm has been testing the combo, on top of two cycles of chemotherapy, for the first-line treatment of advanced non-small cell lung cancer (NSCLC), an important treatment setting for the most deadly form of cancer worldwide.

Shares in the firm were boosted more than 5% in morning trading, following the news that the Phase III CheckMate-9LA trial met its primary endpoint of superior overall survival (OS).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology